Rutgers University researchers find that certain aging immune T cells can blunt cell expansion and may help explain why many ...
This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...
CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...
SurvivorNet on MSN
CAR T-cell therapy and the hope for a cure in multiple myeloma
CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...
There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...
Expanding CAR T beyond academic centers is primarily an access imperative, as travel distance and authorized-site ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present clinical data from its ongoing open-label Phase ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...
Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results